{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:30:23Z","timestamp":1793964623695,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011739","name":"Union des Bless\u00e9s de la Face et de la T\u00eate","doi-asserted-by":"publisher","award":["2012"],"award-info":[{"award-number":["2012"]}],"id":[{"id":"10.13039\/501100011739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic failure) in severely ill burn patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in two tertiary burn intensive care units. DPP3 was measured at admission (DPP3\n                      <jats:sub>admin<\/jats:sub>\n                      ) and 3\u2009days after. The primary endpoint was 90-day mortality. Secondary endpoints were hemodynamic failure and acute kidney injury (AKI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5\u201363) years, with a median total body surface area burned of 35% (25\u201353.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7\u201311). Ninety-day mortality was 32%. The median DPP3\n                      <jats:sub>admin<\/jats:sub>\n                      was significantly higher in non-survivors versus survivors (53.3\u2009ng\/mL [IQR 28.8\u2013103.5] versus 27.1\u2009ng\/mL [IQR 19.4\u201338.9];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Patients with a sustained elevated DPP3 had an increased risk of death compared to patients with high DPP3\n                      <jats:sub>admin<\/jats:sub>\n                      but decreased levels on day 3. Patients with circulatory failure had higher DPP3\n                      <jats:sub>admin<\/jats:sub>\n                      (39.2\u2009ng\/mL [IQR 25.9\u201376.1] versus 28.4\u2009ng\/mL [IQR 19.8\u201339.6];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) as well as patients with AKI (49.7\u2009ng\/mL [IQR 30.3\u201387.3] versus 27.6\u2009ng\/mL [IQR 19.4\u201341.4];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). DPP3\n                      <jats:sub>admin<\/jats:sub>\n                      added prognostic value on top of ABSI (added chi\n                      <jats:sup>2<\/jats:sup>\n                      12.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005), Sequential Organ Failure Assessment (SOFA) score at admission (added chi\n                      <jats:sup>2<\/jats:sup>\n                      4.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0268), and plasma lactate at admission (added chi\n                      <jats:sup>2<\/jats:sup>\n                      6.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0086) to predict circulatory failure within the first 48\u2009h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-020-02888-5","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T14:03:32Z","timestamp":1587564212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients"],"prefix":"10.1186","volume":"24","author":[{"name":"for the PRONOBURN group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"D\u00e9pret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Amzallag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Pollina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Fayolle-Pivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Coutrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eft\u00e9","family":"Chaussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Jully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Fratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikel","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Cupaciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Guillemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Deniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Farny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Textoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2888_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/ALN.0000000000002314","volume":"129","author":"S Soussi","year":"2018","unstructured":"Soussi S, D\u00e9pret F, Benyamina M, Legrand M. Early hemodynamic management of critically ill burn patients. Anesthesiology. 2018;129:583\u20139.","journal-title":"Anesthesiology"},{"key":"2888_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13613-016-0192-y","volume":"6","author":"S Soussi","year":"2016","unstructured":"Soussi S, Deniau B, Ferry A, Lev\u00e9 C, Benyamina M, Maurel V, et al. Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study. Ann Intensive Care. 2016;6:87.","journal-title":"Ann Intensive Care"},{"key":"2888_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/SHK.0000000000001140","volume":"51","author":"S Soussi","year":"2019","unstructured":"Soussi S, Taccori M, De Tymowski C, Depret F, Chaussard M, Fratani A, et al. Risk factors for acute mesenteric ischemia in critically ill burns patients\u2014a matched case\u2013control study. Shock. 2019;51:153\u201360.","journal-title":"Shock"},{"key":"2888_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.burns.2007.11.013","volume":"34","author":"Z Bak","year":"2008","unstructured":"Bak Z, Sj\u00f6berg F, Eriksson O, Steinvall I, Janerot-Sjoberg B. Cardiac dysfunction after burns. Burns. 2008;34:603\u20139.","journal-title":"Burns."},{"key":"2888_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1023\/A:1014943522613","volume":"33","author":"H Zhan","year":"2001","unstructured":"Zhan H, Yamamoto Y, Shumiya S, Kunimatsu M, Nishi K, Ohkubo I, et al. Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats. Histochem J. 2001;33:511\u201321.","journal-title":"Histochem J"},{"key":"2888_CR6","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1111\/j.1742-4658.2011.08275.x","volume":"278","author":"SC Prajapati","year":"2011","unstructured":"Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter: dipeptidyl peptidase III. FEBS J. 2011;278:3256\u201376.","journal-title":"FEBS J"},{"key":"2888_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.116.07357","volume":"68","author":"X Pang","year":"2016","unstructured":"Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, et al. Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertension. 2016;68:630\u201341.","journal-title":"Hypertension."},{"key":"2888_CR8","doi-asserted-by":"publisher","unstructured":"Dale CS, Pagano R de L, Rioli V. Hemopressin: a novel bioactive peptide derived from the \u03b11-chain of hemoglobin. p. 2. https:\/\/doi.org\/10.1590\/s0074-02762005000900017.","DOI":"10.1590\/s0074-02762005000900017"},{"key":"2888_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0196-0644(82)80096-6","volume":"11","author":"J Tobiasen","year":"1982","unstructured":"Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann Emerg Med. 1982;11:260\u20132.","journal-title":"Ann Emerg Med"},{"key":"2888_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00000658-194908000-00002","volume":"130","author":"JP Bull","year":"1949","unstructured":"Bull JP, Squire JR. A study of mortality in a burns unit: standards for the evaluation of alternative methods of treatment. Ann Surg. 1949;130:160.","journal-title":"Ann Surg"},{"key":"2888_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"2888_CR12","doi-asserted-by":"publisher","unstructured":"Soussi S, D\u00e9pret F, Benyamina M, Legrand M. Anesthesiology. 2018;129(3):583\u20139. https:\/\/doi.org\/10.1097\/ALN.0000000000002314.","DOI":"10.1097\/ALN.0000000000002314"},{"key":"2888_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0002-8703(82)90233-2","volume":"104","author":"S Rich","year":"1982","unstructured":"Rich S, Sheikh A, Gallastegui J, Kondos GT, Mason T, Lam W. Determination of left ventricular ejection fraction by visual estimation during real-time two-dimensional echocardiography. Am Heart J. 1982;104:603\u20136.","journal-title":"Am Heart J"},{"key":"2888_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, For the KDIGO AKI guideline work group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17:204.","journal-title":"Crit Care"},{"key":"2888_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1373\/jalm.2018.027995","volume":"3","author":"L Rehfeld","year":"2019","unstructured":"Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med. 2019;3:943\u201353.","journal-title":"J Appl Lab Med"},{"key":"2888_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMra1807442","volume":"380","author":"DG Greenhalgh","year":"2019","unstructured":"Greenhalgh DG. Management of burns. N Engl J Med. 2019;380:2349\u201359.","journal-title":"N Engl J Med"},{"key":"2888_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CCM.0000000000000790","volume":"43","author":"MG Jeschke","year":"2015","unstructured":"Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. Crit Care Med. 2015;43:808\u201315.","journal-title":"Crit Care Med"},{"key":"2888_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00134-014-3627-7","volume":"41","author":"M Legrand","year":"2015","unstructured":"Legrand M, Guttormsen AB, Berger MM. Ten tips for managing critically ill burn patients: follow the RASTAFARI! Intensive Care Med. 2015;41:1107\u20139.","journal-title":"Intensive Care Med"},{"key":"2888_CR19","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","volume":"394","author":"C Ronco","year":"2019","unstructured":"Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet Lond Engl. 2019;394:1949\u201364.","journal-title":"Lancet Lond Engl"},{"key":"2888_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jcrc.2015.05.003","volume":"30","author":"BT Wong","year":"2015","unstructured":"Wong BT, Chan MJ, Glassford NJ, M\u00e5rtensson J, Bion V, Chai SY, et al. Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. J Crit Care. 2015;30:975\u201381.","journal-title":"J Crit Care"},{"key":"2888_CR21","doi-asserted-by":"publisher","unstructured":"Deniau B, Rehfeld L, Santos K, Dienelt A, Azibani F, Sadoune M, Kounde PR, Samuel JL, Tolpannen H, Lassus J, Harjola VP, Vodovar N, Bergmann A, Hartmann O, Mebazaa A, Blet A. Eur J Heart Fail. 2020;22(2):290\u20139. https:\/\/doi.org\/10.1002\/ejhf.1601.","DOI":"10.1002\/ejhf.1601"},{"key":"2888_CR22","doi-asserted-by":"publisher","unstructured":"Takagi K, Blet A, Levy B, Deniau B, Azibani F, Feliot E, Bergmann A, Santos K, Hartmann O, Gayat E, Mebazaa A, Kimmoun A. Eur J Heart Fail. 2020;22(2):279\u201386. https:\/\/doi.org\/10.1002\/ejhf.1600.","DOI":"10.1002\/ejhf.1600"},{"key":"2888_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1213\/ANE.0000000000004343","volume":"130","author":"JH Chow","year":"2020","unstructured":"Chow JH, Abuelkasem E, Sankova S, Henderson RA, Mazzeffi MA, Tanaka KA. Reversal of vasodilatory shock: current perspectives on conventional, rescue, and emerging vasoactive agents for the treatment of shock. Anesth Analg. 2020;130:15\u201330.","journal-title":"Anesth Analg"},{"key":"2888_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419\u201330.","journal-title":"N Engl J Med"},{"key":"2888_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MCC.0000000000000517","volume":"24","author":"BJ Wakefield","year":"2018","unstructured":"Wakefield BJ, Sacha GL, Khanna AK. Vasodilatory shock in the ICU and the role of angiotensin II. Curr Opin Crit Care. 2018;24:277\u201385.","journal-title":"Curr Opin Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-02888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-020-02888-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-02888-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T20:06:07Z","timestamp":1619035567000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-02888-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2888"],"URL":"https:\/\/doi.org\/10.1186\/s13054-020-02888-5","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by our local research ethical committee (Comit\u00e9 de Protection des Personnes 2013\/17NICB).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FD has received research grants from the French ministry of health, Soci\u00e9t\u00e9 fran\u00e7aise d\u2019anesth\u00e9sie reanimation, European Society of Intensive Care Medicine, and lecture fees Sedana medical.JA has no conflict of interest.MCo has no conflict of interest.MCh has no conflict of interest.KS and OH are employed by 4TEEN4 Pharmaceuticals GmbH, a company which holds patent rights in and commercializes the DPP3 assay.MJ has no conflict of interest.AF has no conflict of interest.HO has no conflict of interest.AC has no conflict of interest.MB has no conflict of interest.LG has no conflict of interest.BD received research grant from 4TEEN4 Pharmaceuticals GmbH.AM has received speaker\u2019s honoraria from Novartis, Orion, and Servier and fees as a member of the advisory board and\/or steering committee from Cardiorentis, Adrenomed, sphingotec, Sanofi, Roche, Abbott, and Bristol-Myers Squibb.BS has no conflict of interest.JT is employed by Biomerieux.ML has received research grants from the French ministry of health, lecture fees from Baxter, and Fresenius and research support from Sphingotec.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}